Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierNovartis is an innovative medicines company, engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of pharmaceutical products. Our purpose is to reimagine medicine to improve and extend people’s lives. Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. To support our strategy, we have clear focus areas where we commit most of our time, energy and resources.
In the company’s own words · 20-F filed Feb 4, 2026 · SEC EDGAR
Novartis AG (NVS) reported revenue of $27.2B in H2 2025 (quarter ended Dec 31, 2025), up 118% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $6.34B (23% of revenue). For the full year FY2025, revenue was $54.5B (+8.4% year on year) and net income $14.0B.
Raw charts
7 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
Ranks #2 of 7 by Smart Score